Sign up to SCR Digest, our FREE weekly newsletter, and receive our Notes emailed directly to you.
Email Address *
First Name
Mailing Lists *
















































































































OPNT: Receives Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization

08-10-2017
By David Bautz, PhD

OTC:OPNT

Business Update

Opiant Receives Additional $3.75 Million Payment From SWK

On August 10, 2017, Opiant Pharmaceuticals Inc. (OTC:OPNT) announced an additional $3.75 million payment from SWK Holdings Corporation related to the royalty monetization agreement related to the sale of NARCAN® Nasal Spray signed between Opiant and SWK in December 2016. According to the agreement, the $3.75 million payment was due to Opiant upon Adapt Pharma recording >$25 million in cumulative net sales of NARCAN® Nasal Spray for any two consecutive quarters from Oct. 1, 2016 to Sep. 30, 2017. This occurred over the first two quarters of 2017. 

The royalty monetization agreement with SWK stipulates that SWK will receive all royalties on the sale of NARCAN® Nasal Spray up to $26.25 million dollars. Following that, the royalty rights will revert back to Opiant and SWK will receive a residual royalty of 10% on all royalties from the sale of NARCAN® Nasal Spray. 

Presidential Task Force Recommends Co-Prescribing of Opioid Overdoes Treatments

On March 29, 2017, President Trump signed an Executive Order establishing the President’s Commission on Combating Drug Addiction and the Opioid Crisis. The Commission issued a draft interim report on July 31, 2017 that included a number of different recommendations to help combat the increased use of drugs, particularly opioids. Among those is a recommendation that all states should have a standing order to allow dispensing of naloxone, that naloxone should be required to be co-prescribed with any high-risk opioid prescription, and that all law enforcement officials in the U.S. should carry naloxone. 

As the following chart shows, there has been a significant increase in the number of states that allow the prescribing of naloxone by standing order, however the President’s Commission is pushing for all states to have a standing order for naloxone.

The requirement for co-prescribing of naloxone would be a significant development for companies that sell naloxone as there are an estimated 227 million opioid prescriptions written in the U.S. every year. In addition, as the opioid crisis continues to worsen, payers are likely to be receptive to covering naloxone with little to no co-pay. We believe Opiant would be a prime benefactor from a required co-prescription of naloxone, as NARCAN® Nasal Spray is a simple and affordable means by which to administer naloxone. However, even with the requirement for co-prescribing naloxone it would still be necessary to get patients comfortable with the idea of being prescribed an anti-overdose treatment and potentially paying for something that most would deem unnecessary.  

Conclusion

The $3.75 million payment from SWK occurred sooner than we had modeled for, and we believe this is evidence of NARCAN® Nasal Spray selling well above our estimates. Adapt Pharma is a private company, thus we are unable to ascertain exact revenues of NARCAN® Nasal Spray. Before monetizing the royalties, Opiant received $105,097, $234,498, and $524,142 in royalties for NARCAN® Nasal Spray for the first, second, and third quarters of 2016, respectively. Those royalty numbers point to a rapid rise in sales of NARCAN® Nasal Spray (we model for a composite 11% royalty), and with at least $25 million in sales for the first two quarters of 2017, we believe that SWK may receive $26.25 million in royalties and milestone payments sooner than we had originally thought. We now model for royalties to revert back to Opiant in 2020, with peak sales of NARCAN® Nasal Spray of $250 million. 

Opiant’s (OTC:OPNT) stock price has increased approximately 250% just in the past month, however we believe there may be upside to the story as the company now has additional capital to advance its pipeline in alcohol use disorder, bulimia nervosa, and cocaine use disorder. In addition, sales of NARCAN® Nasal Spray may continue to surpass our expectations, particularly if the recommendations of the Presidential Commission are enacted. Following the adjustments to our model, our valuation for Opiant has increased to $30 per share.   

READ THE FULL RESEARCH REPORT HERE

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR and to view our disclaimer.

 
User ID:
Password:
Remember my ID: